News & Events

Show:
December 1, 2020

Evercore ISI 3rd Annual HealthCONx Virtual Conference

Event Date: December 3, 2020

READ MORE
November 23, 2020

Crinetics Pharmaceuticals to Participate in December Investor Conferences

Dr. Scott Struthers and Dr. Alan Krasner present at 32nd annual Piper Sandler Healthcare Conference December 1st-3rd, 2020 Webcast available until...

READ MORE
November 16, 2020

Crinetics Pharmaceuticals Appoints Acromegaly Expert, Peter Trainer, Vice President of Clinical Endocrinology

“Dr. Trainer is a global leader in the endocrine community who has treated patients, published extensively and educated physicians on...

READ MORE
November 13, 2020

KOL Call: Paltusotine for the Treatment of Acromegaly

Event Date: November 20, 2020

READ MORE
November 13, 2020

Crinetics Hosting Key Opinion Leader Meeting Focusing on Oral Paltusotine for Treatment of Acromegaly

Crinetics hosts a virtual Key Opinion Leader (KOL) meeting on oral paltusotine for the treatment of acromegaly on Friday, November...

READ MORE
November 6, 2020

Third Quarter 2020 Financial Results and Corporate Update

Positive topline results for Phase 2 trials of oral paltusotine (acromegaly), CRN04777 received Rare Pediatric Disease Designation (congenital hyperinsulinism)

READ MORE
November 1, 2020

32nd Annual Piper Sandler Healthcare Conference

Event Date: December 1–3, 2020

READ MORE
October 26, 2020

Company Conference Call: Review of Phase 2 Paltusotine Results

Event Date: October 26, 2020

READ MORE
October 26, 2020

ACROBAT Edge Study of Paltusotine in Acromegaly Met Endpoint

Crinetics announces Paltusotine (for treatment of acromegaly) was observed to be safe and well-tolerated among the 60 participants in the...

READ MORE
September 21, 2020

Crinetics Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for CRN04777 for the Treatment of Congenital Hyperinsulinism

FDA grants rare pediatric disease designation: CRN04777 - investigational, orally available, SST5 agonist developing as treatment for congenital hyperinsulinism.

READ MORE